Skip to main content
Top
Published in: Obesity Surgery 12/2018

01-12-2018 | Original Contributions

Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?

Authors: Carlos Martin Esquivel, Manuel Garcia, Lucas Armando, Guillermo Ortiz, Fernando Martínez Lascano, José María Foscarini

Published in: Obesity Surgery | Issue 12/2018

Login to get access

Abstract

Introduction

Obesity is strongly associated with non-alcoholic fatty liver disease (NAFLD); 66–99% of the obese population could suffer some grade of NAFLD. It can progress into cirrhosis, which is associated to hepatocellular carcinoma, and a liver transplant could be indicated. NAFLD represents the third cause of liver transplant, and it is expected to be the first by 2025. Sleeve gastrectomy (SG) is the most common bariatric procedure over the world. There is scant literature regarding NAFLD after SG, and there are no prospective studies published up to date.

Objective

To evaluate the evolution of NAFLD in patients with obesity after 1 year of SG.

Methods

From January 2009 to December 2013, intraoperative liver biopsy was performed in 63 obese patients who underwent SG. Forty-three patients were again biopsied 1 year after surgery. Demographics, body mass index, percentage of excess weight loss, liver function test, lipid panel, glucose panel, and histological changes were prospectively analyzed.

Results

One hundred percent of the patients reversed or reduced the stage of steatosis or steatohepatitis 12 months after surgery, obtaining a statistically significant difference for both steatosis and steatohepatitis. One patient presented complete cirrhosis regression in the pathology. Neither of the patients had worsened liver histology.

Conclusions

NAFLD could be dealt with laparoscopic sleeve gastrectomy, preventing its progression into cirrhosis. SG can be performed in patients with obesity and metabolic syndrome, with NAFLD showing satisfactory results 12 months after surgery. NAFLD should be a formal indication for bariatric surgery.
Literature
1.
go back to reference WHO. Obesity: preventing and managing the global epidemic, report of WHO consultation on obesity, Technical Report Series No. 894. Geneva: World Health Organization; 2000. p. 256. WHO. Obesity: preventing and managing the global epidemic, report of WHO consultation on obesity, Technical Report Series No. 894. Geneva: World Health Organization; 2000. p. 256.
2.
go back to reference Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–50.CrossRef Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844–50.CrossRef
3.
go back to reference Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.CrossRef Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.CrossRef
4.
go back to reference Lima M, Mourao S, Diniz M, et al. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg. 2005;15(5):661–9.CrossRef Lima M, Mourao S, Diniz M, et al. Hepatic histopathology of patients with morbid obesity submitted to gastric bypass. Obes Surg. 2005;15(5):661–9.CrossRef
5.
go back to reference Ruderman N, Chisholm D, Pi-Sunyer X, et al. The metabolically obese, normal weight individual revisited. Diabetes. 1998;47(5):699–713.CrossRef Ruderman N, Chisholm D, Pi-Sunyer X, et al. The metabolically obese, normal weight individual revisited. Diabetes. 1998;47(5):699–713.CrossRef
6.
go back to reference Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.CrossRef Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology. 2002;123(1):134–40.CrossRef
8.
go back to reference Wang R, Koretz R, Yee H. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med. 2003;115:554–9.CrossRef Wang R, Koretz R, Yee H. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med. 2003;115:554–9.CrossRef
9.
go back to reference Blackburn G, Mun E. Effects of weight loss surgeries on liver disease. Semin Liver Dis. 2004;24(4):371–9.CrossRef Blackburn G, Mun E. Effects of weight loss surgeries on liver disease. Semin Liver Dis. 2004;24(4):371–9.CrossRef
11.
go back to reference Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593–608.CrossRef Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58(3):593–608.CrossRef
12.
go back to reference Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17(Suppl):S186–90.CrossRef Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17(Suppl):S186–90.CrossRef
13.
go back to reference Gupta R, Bhangoo A, Matthews NA, et al. The prevalence of nonalcoholic fatty liver disease and metabolic syndrome in obese children. J Pediatr Endocrinol Metab. 2011;24(11–12):907–11.PubMed Gupta R, Bhangoo A, Matthews NA, et al. The prevalence of nonalcoholic fatty liver disease and metabolic syndrome in obese children. J Pediatr Endocrinol Metab. 2011;24(11–12):907–11.PubMed
14.
go back to reference Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32(9):1431–7.CrossRef Kelly T, Yang W, Chen CS, et al. Global burden of obesity in 2005 and projections to 2030. Int J Obes. 2008;32(9):1431–7.CrossRef
15.
go back to reference Ludwig J, Viaggiano TR, McGill DB, et al. Non-alcoholic steatohepatitis: Mayo clinic experience with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.PubMed Ludwig J, Viaggiano TR, McGill DB, et al. Non-alcoholic steatohepatitis: Mayo clinic experience with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434–8.PubMed
16.
go back to reference Erby JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med. 2000;109(7):588–90.CrossRef Erby JR, Silberman C, Lydick E. Prevalence of abnormal serum alanine aminotransferase levels in obese patients and patients with type 2 diabetes. Am J Med. 2000;109(7):588–90.CrossRef
17.
go back to reference Matteoni CA, Younossi ZM, Gramlich T, et al. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413–9.CrossRef Matteoni CA, Younossi ZM, Gramlich T, et al. Non-alcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413–9.CrossRef
18.
go back to reference Caldwell SH, Hespenheide EE. Sub-acute liver failure in obese women. Am J Gastroenterol. 2002;97(8):2058–62.CrossRef Caldwell SH, Hespenheide EE. Sub-acute liver failure in obese women. Am J Gastroenterol. 2002;97(8):2058–62.CrossRef
19.
go back to reference Shimada M, Hashimoto E, Tania M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002;37:154–60.CrossRef Shimada M, Hashimoto E, Tania M, et al. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2002;37:154–60.CrossRef
20.
go back to reference Hashizume H, Sato K, Takagi H, et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2007;19:827–34.CrossRef Hashizume H, Sato K, Takagi H, et al. Primary liver cancers with nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2007;19:827–34.CrossRef
21.
go back to reference Targher G, Day CP, Bonora E. Risk of cardiovascular disease in non-alcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.CrossRef Targher G, Day CP, Bonora E. Risk of cardiovascular disease in non-alcoholic fatty liver disease. N Engl J Med. 2010;363(14):1341–50.CrossRef
22.
go back to reference Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820–6.PubMed Fassio E, Alvarez E, Dominguez N, et al. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820–6.PubMed
23.
go back to reference Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis. 2009;13(4):649–65.CrossRef Neuschwander-Tetri BA. Lifestyle modification as the primary treatment of NASH. Clin Liver Dis. 2009;13(4):649–65.CrossRef
24.
go back to reference Laurin J, Lindor K, Crippin J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. Hepatology. 1996;23(6):1464–7.CrossRef Laurin J, Lindor K, Crippin J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcoholic-induced steatohepatitis: a pilot study. Hepatology. 1996;23(6):1464–7.CrossRef
25.
go back to reference Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004;20(6):623–8.CrossRef Harrison SA, Fincke C, Helinski D, et al. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther. 2004;20(6):623–8.CrossRef
26.
go back to reference Lindor KD, Kowdley KV, Heathcote JE, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39(3):770–8.CrossRef Lindor KD, Kowdley KV, Heathcote JE, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39(3):770–8.CrossRef
27.
go back to reference Anjana AP, Rinella ME. Non-alcoholic liver disease: is bariatric surgery the answer. Clin Liver Dis. 2009;13(4):689–710.CrossRef Anjana AP, Rinella ME. Non-alcoholic liver disease: is bariatric surgery the answer. Clin Liver Dis. 2009;13(4):689–710.CrossRef
28.
go back to reference MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastroenterol Surg. 1997;1(3):213–20. discussion 220CrossRef MacDonald KG, Long SD, Swanson MS, et al. The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastroenterol Surg. 1997;1(3):213–20. discussion 220CrossRef
29.
go back to reference Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13.CrossRef Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—3-year outcomes. N Engl J Med. 2014;370(21):2002–13.CrossRef
30.
go back to reference Hocking MP, Davis GL, Franzini DA, et al. Long-term consequences after jejunoileal bypass for morbid obesity. Dig Dis Sci. 1998;43(11):2493–9.CrossRef Hocking MP, Davis GL, Franzini DA, et al. Long-term consequences after jejunoileal bypass for morbid obesity. Dig Dis Sci. 1998;43(11):2493–9.CrossRef
31.
go back to reference Grimm I, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol. 1992;87(6):775–9.PubMed Grimm I, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion. Am J Gastroenterol. 1992;87(6):775–9.PubMed
32.
go back to reference Furuya Jr CK, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol. 2007;22(4):510–4.CrossRef Furuya Jr CK, de Oliveira CP, de Mello ES, et al. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years. J Gastroenterol Hepatol. 2007;22(4):510–4.CrossRef
33.
go back to reference Liu X, Lazenby AJ, Clements RH, et al. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg. 2007;17(4):486–92.CrossRef Liu X, Lazenby AJ, Clements RH, et al. Resolution of nonalcoholic steatohepatitis after gastric bypass surgery. Obes Surg. 2007;17(4):486–92.CrossRef
34.
go back to reference Tai CM, Huang CK, Hwang JC, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg. 2012;22(7):1016–21.CrossRef Tai CM, Huang CK, Hwang JC, et al. Improvement of nonalcoholic fatty liver disease after bariatric surgery in morbidly obese Chinese patients. Obes Surg. 2012;22(7):1016–21.CrossRef
35.
go back to reference Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):274–9.CrossRef Weiner RA. Surgical treatment of non-alcoholic steatohepatitis and non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):274–9.CrossRef
36.
go back to reference Froylich D, Corcelles R, Daigle C, et al. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12(1):127–31.CrossRef Froylich D, Corcelles R, Daigle C, et al. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12(1):127–31.CrossRef
37.
go back to reference Moretto M, Kupski C, da Silva VD, et al. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22(7):1044–9.CrossRef Moretto M, Kupski C, da Silva VD, et al. Effect of bariatric surgery on liver fibrosis. Obes Surg. 2012;22(7):1044–9.CrossRef
38.
go back to reference Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9.CrossRef Bower G, Toma T, Harling L, et al. Bariatric surgery and non-alcoholic fatty liver disease: a systematic review of liver biochemistry and histology. Obes Surg. 2015;25(12):2280–9.CrossRef
39.
go back to reference Sieber P, Gass M, Kern B, et al. Five-year results of laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2014;10(2):243–9.CrossRef Sieber P, Gass M, Kern B, et al. Five-year results of laparoscopic sleeve gastrectomy. Surg Obes Relat Dis. 2014;10(2):243–9.CrossRef
40.
go back to reference Strain GW, Saif T, Gagner M, et al. Cross-sectional review of effects of laparoscopic sleeve gastrectomy at 1, 3, and 5 years. Surg Obes Relat Dis. 2011;7(6):714–9.CrossRef Strain GW, Saif T, Gagner M, et al. Cross-sectional review of effects of laparoscopic sleeve gastrectomy at 1, 3, and 5 years. Surg Obes Relat Dis. 2011;7(6):714–9.CrossRef
41.
go back to reference Brethauer SA, Hammel JP, Schauer PR. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis. 2009;5(4):469–75.CrossRef Brethauer SA, Hammel JP, Schauer PR. Systematic review of sleeve gastrectomy as staging and primary bariatric procedure. Surg Obes Relat Dis. 2009;5(4):469–75.CrossRef
42.
go back to reference Trastulli S, Desiderio J, Guarino S, et al. Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surg Obes Relat Dis. 2013;9(5):816–29.CrossRef Trastulli S, Desiderio J, Guarino S, et al. Laparoscopic sleeve gastrectomy compared with other bariatric surgical procedures: a systematic review of randomized trials. Surg Obes Relat Dis. 2013;9(5):816–29.CrossRef
43.
go back to reference Strain GW, Saif T, Ebel F, et al. Lipid profile changes in the severely obese after laparoscopic sleeve gastrectomy (LSG), 1, 3, and 5 years after surgery. Obes Surg. 2015;25(2):285–9.CrossRef Strain GW, Saif T, Ebel F, et al. Lipid profile changes in the severely obese after laparoscopic sleeve gastrectomy (LSG), 1, 3, and 5 years after surgery. Obes Surg. 2015;25(2):285–9.CrossRef
44.
go back to reference Benetti A, Del Puppo M, Crosignani A, et al. Cholesterol metabolism after bariatric surgery in grade 3 obesity: differences between malabsorptive and restrictive procedures. Diabetes Care. 2013;36(6):1443–7.CrossRef Benetti A, Del Puppo M, Crosignani A, et al. Cholesterol metabolism after bariatric surgery in grade 3 obesity: differences between malabsorptive and restrictive procedures. Diabetes Care. 2013;36(6):1443–7.CrossRef
45.
go back to reference Benaiges D, Flores-Le-Roux JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22(8):1268–75.CrossRef Benaiges D, Flores-Le-Roux JA, Pedro-Botet J, et al. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes Surg. 2012;22(8):1268–75.CrossRef
46.
go back to reference Zhang F, Strain GW, Lei W, et al. Changes in lipid profiles in morbidly obese patients after laparoscopic sleeve gastrectomy (LSG). Obes Surg. 2011;21(3):305–9.CrossRef Zhang F, Strain GW, Lei W, et al. Changes in lipid profiles in morbidly obese patients after laparoscopic sleeve gastrectomy (LSG). Obes Surg. 2011;21(3):305–9.CrossRef
47.
go back to reference Brehm A, Pfeiler G, Pacini G, et al. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem. 2004;50(12):2316–22.CrossRef Brehm A, Pfeiler G, Pacini G, et al. Relationship between serum lipoprotein ratios and insulin resistance in obesity. Clin Chem. 2004;50(12):2316–22.CrossRef
48.
go back to reference Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719–25.CrossRef Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(6):2719–25.CrossRef
49.
go back to reference Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and post prandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247(3):401–7.CrossRef Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and post prandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008;247(3):401–7.CrossRef
50.
go back to reference Van den Hoek AM, Heijboer AC, Voshol PJ, et al. Chronic PYY3–36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab. 2007;292(1):E238–45.CrossRef Van den Hoek AM, Heijboer AC, Voshol PJ, et al. Chronic PYY3–36 treatment promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J Physiol Endocrinol Metab. 2007;292(1):E238–45.CrossRef
51.
go back to reference Djurhuus CB, Hansen TK, Gravholt C, et al. Circulating levels of ghrelin and GLP-1 are inversely related during glucose ingestion. Horm Metab Res. 2002;34(7):411–3.CrossRef Djurhuus CB, Hansen TK, Gravholt C, et al. Circulating levels of ghrelin and GLP-1 are inversely related during glucose ingestion. Horm Metab Res. 2002;34(7):411–3.CrossRef
52.
go back to reference Liou JM, Lin JT, Lee WJ, et al. The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery. Obes Surg. 2008;18(1):84–9.CrossRef Liou JM, Lin JT, Lee WJ, et al. The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery. Obes Surg. 2008;18(1):84–9.CrossRef
53.
go back to reference Kotidis EV, Koliakos G, Papavramidis TS, et al. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight reducing effect of this procedure? Obes Surg. 2006;16(5):554–9.CrossRef Kotidis EV, Koliakos G, Papavramidis TS, et al. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight reducing effect of this procedure? Obes Surg. 2006;16(5):554–9.CrossRef
54.
go back to reference Geloneze B, Tambascia MA, Repetto EM, et al. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg. 2001;11(6):693–8.CrossRef Geloneze B, Tambascia MA, Repetto EM, et al. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg. 2001;11(6):693–8.CrossRef
55.
go back to reference Moon Han S, Kim WW, Oh JH. Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients. Obes Surg. 2005;15(10):1469–75.CrossRef Moon Han S, Kim WW, Oh JH. Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients. Obes Surg. 2005;15(10):1469–75.CrossRef
56.
go back to reference Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18(9):1077–82.CrossRef Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008;18(9):1077–82.CrossRef
57.
go back to reference Rizzello M, Abbatini F, Casella G, et al. Early postoperative insulin-resistance changes after sleeve gastrectomy. Obes Surg. 2010;20(1):50–5.CrossRef Rizzello M, Abbatini F, Casella G, et al. Early postoperative insulin-resistance changes after sleeve gastrectomy. Obes Surg. 2010;20(1):50–5.CrossRef
58.
go back to reference Gaur A, Naidu CS, Rao PP, et al. The effect of laparoscopic sleeve gastrectomy (LSG) on glycemic control in morbidly obese patients. Int J Surg. 2016;28:131–5.CrossRef Gaur A, Naidu CS, Rao PP, et al. The effect of laparoscopic sleeve gastrectomy (LSG) on glycemic control in morbidly obese patients. Int J Surg. 2016;28:131–5.CrossRef
59.
go back to reference Slater BJ, Bellatorre N, Eisenberg D. Early postoperative outcomes and medication cost savings after laparoscopic sleeve gastrectomy in morbidly obese patients with type 2 diabetes. J Obes. 2011;2011:350523.CrossRef Slater BJ, Bellatorre N, Eisenberg D. Early postoperative outcomes and medication cost savings after laparoscopic sleeve gastrectomy in morbidly obese patients with type 2 diabetes. J Obes. 2011;2011:350523.CrossRef
60.
go back to reference Bayham BE, Greenway FL, Bellanger DE, et al. Early resolution of type 2 diabetes seen after Roux-en-Y gastric bypass and vertical sleeve gastrectomy. Diabetes Technol Ther. 2012;14(1):30–4.CrossRef Bayham BE, Greenway FL, Bellanger DE, et al. Early resolution of type 2 diabetes seen after Roux-en-Y gastric bypass and vertical sleeve gastrectomy. Diabetes Technol Ther. 2012;14(1):30–4.CrossRef
61.
go back to reference Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763–77.CrossRef Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763–77.CrossRef
62.
go back to reference Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6(6):707–13.CrossRef Gill RS, Birch DW, Shi X, et al. Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. 2010;6(6):707–13.CrossRef
63.
go back to reference Atkins ER, Preen DB, Jarman C, et al. Improved obesity reduction and co-morbidity resolution in patients treated with 40-French bougie versus 50-French bougie four years after laparoscopic sleeve gastrectomy: analysis of 294 patients. Obes Surg. 2012;22(1):97–104.CrossRef Atkins ER, Preen DB, Jarman C, et al. Improved obesity reduction and co-morbidity resolution in patients treated with 40-French bougie versus 50-French bougie four years after laparoscopic sleeve gastrectomy: analysis of 294 patients. Obes Surg. 2012;22(1):97–104.CrossRef
64.
go back to reference Golomb I, Ben David M, Glass A, et al. Long-term metabolic effects of laparoscopic sleeve gastrectomy. JAMA Surg. 2015;150(11):1051–7.CrossRef Golomb I, Ben David M, Glass A, et al. Long-term metabolic effects of laparoscopic sleeve gastrectomy. JAMA Surg. 2015;150(11):1051–7.CrossRef
65.
go back to reference Rosenthal R, Li X, Samuel S, et al. Effect of sleeve gastrectomy on patients with diabetes mellitus. Surg Obes Relat Dis. 2009;5(4):429–34.CrossRef Rosenthal R, Li X, Samuel S, et al. Effect of sleeve gastrectomy on patients with diabetes mellitus. Surg Obes Relat Dis. 2009;5(4):429–34.CrossRef
Metadata
Title
Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?
Authors
Carlos Martin Esquivel
Manuel Garcia
Lucas Armando
Guillermo Ortiz
Fernando Martínez Lascano
José María Foscarini
Publication date
01-12-2018
Publisher
Springer US
Published in
Obesity Surgery / Issue 12/2018
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-018-3466-7

Other articles of this Issue 12/2018

Obesity Surgery 12/2018 Go to the issue